WO2003094839A8 - Pyrimidinone compounds, compositions and methods - Google Patents
Pyrimidinone compounds, compositions and methodsInfo
- Publication number
- WO2003094839A8 WO2003094839A8 PCT/US2003/013627 US0313627W WO03094839A8 WO 2003094839 A8 WO2003094839 A8 WO 2003094839A8 US 0313627 W US0313627 W US 0313627W WO 03094839 A8 WO03094839 A8 WO 03094839A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- methods
- pyrimidinone compounds
- compounds
- pyrimidinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04011074A MXPA04011074A (en) | 2002-05-09 | 2003-05-02 | Pyrimidinone compounds, compositions and methods. |
NZ537076A NZ537076A (en) | 2002-05-09 | 2003-05-02 | Pyrimidinone compounds, compositions and methods |
AU2003223786A AU2003223786A1 (en) | 2002-05-09 | 2003-05-02 | Compounds, methods and compositions |
EP03719989A EP1503993A4 (en) | 2002-05-09 | 2003-05-02 | Compounds, methods and compositions |
BRPI0309892-3A BR0309892A2 (en) | 2002-05-09 | 2003-05-02 | compound, composition, methods for modulating ksp kinesin activity, inhibiting ksp, and for treating a cell proliferative disease, and use of a compound |
CA002485148A CA2485148A1 (en) | 2002-05-09 | 2003-05-02 | Pyrimidinone compounds, compositions and methods |
JP2004502928A JP2006508030A (en) | 2002-05-09 | 2003-05-02 | Pyrimidinone compounds, compositions and methods |
IS7520A IS7520A (en) | 2002-05-09 | 2004-11-03 | Pyrimidinone Compounds, Compositions and Methods |
IL16504604A IL165046A0 (en) | 2002-05-09 | 2004-11-04 | Pyrimidinone compounds, compositions and methods |
NO20045043A NO20045043L (en) | 2002-05-09 | 2004-11-19 | Pyrimidinone Compounds, Compositions and Methods |
IL187528A IL187528A0 (en) | 2002-05-09 | 2007-11-20 | Use of pyrimidine compounds in the manufacture of medicaments |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37965802P | 2002-05-09 | 2002-05-09 | |
US60/379,658 | 2002-05-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003094839A2 WO2003094839A2 (en) | 2003-11-20 |
WO2003094839A8 true WO2003094839A8 (en) | 2004-06-24 |
WO2003094839A3 WO2003094839A3 (en) | 2004-09-16 |
Family
ID=29420548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/013627 WO2003094839A2 (en) | 2002-05-09 | 2003-05-02 | Pyrimidinone compounds, compositions and methods |
Country Status (20)
Country | Link |
---|---|
US (2) | US7166595B2 (en) |
EP (1) | EP1503993A4 (en) |
JP (1) | JP2006508030A (en) |
KR (1) | KR20050036911A (en) |
CN (1) | CN100491358C (en) |
AR (1) | AR039985A1 (en) |
AU (1) | AU2003223786A1 (en) |
BR (1) | BR0309892A2 (en) |
CA (1) | CA2485148A1 (en) |
IL (2) | IL165046A0 (en) |
IS (1) | IS7520A (en) |
MX (1) | MXPA04011074A (en) |
MY (1) | MY140767A (en) |
NO (1) | NO20045043L (en) |
NZ (1) | NZ537076A (en) |
PL (1) | PL373412A1 (en) |
RU (1) | RU2004135554A (en) |
TW (1) | TW200406387A (en) |
WO (1) | WO2003094839A2 (en) |
ZA (1) | ZA200409881B (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
EP1551812B1 (en) * | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
JP2005529076A (en) * | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | Synthesis of quinazolinone |
EP1553931A4 (en) * | 2002-05-09 | 2006-08-30 | Cytokinetics Inc | Compounds, compositions, and methods |
JP2006508030A (en) * | 2002-05-09 | 2006-03-09 | サイトキネティクス・インコーポレーテッド | Pyrimidinone compounds, compositions and methods |
US20050234080A1 (en) * | 2002-05-23 | 2005-10-20 | Coleman Paul J | Mitotic kinesin inhibitors |
US7038048B2 (en) * | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
JP2005538062A (en) * | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
EP1537089A4 (en) * | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | Compounds compositions and methods |
EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | Compounds, compositions, and methods |
US7557115B2 (en) * | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
EP1601673B1 (en) * | 2003-03-07 | 2009-06-10 | AstraZeneca AB | Fused heterocycles and uses thereof |
WO2006018628A1 (en) * | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
EP1680420A4 (en) * | 2003-11-07 | 2008-09-24 | Cytokinetics Inc | Compounds, compositions, and methods |
WO2005061460A1 (en) * | 2003-12-08 | 2005-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
JP2007518711A (en) | 2003-12-19 | 2007-07-12 | メルク エンド カムパニー インコーポレーテッド | Mitotic kinesin inhibitor |
CA2558214A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
PL1732926T3 (en) * | 2004-04-06 | 2009-06-30 | Novartis Vaccines & Diagnostics Inc | Mitotic kinesin inhibitors |
AU2005245492A1 (en) | 2004-05-21 | 2005-12-01 | Novartis Vaccines And Diagnostics, Inc. | Substituted quinoline derivatives as mitotic kinesin inhibitors |
MXPA06014909A (en) * | 2004-06-18 | 2007-02-28 | Chiron Corp | N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer. |
US7271271B2 (en) * | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
US7375102B2 (en) * | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
EP1773830A1 (en) * | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
CA2575188A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
EP2275412A1 (en) | 2004-10-19 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Indole and benzimidazole derivatives |
US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
TW200716102A (en) * | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
ES2557478T3 (en) | 2006-11-13 | 2016-01-26 | Novartis Ag | Pyrazole and triazole compounds as KSP inhibitors |
JP2010515687A (en) | 2007-01-05 | 2010-05-13 | ノバルティス アーゲー | Imidazole derivatives as kinesin spindle protein inhibitors (EG-5) |
EP2070932A1 (en) * | 2007-12-13 | 2009-06-17 | 4Sc Ag | Pyrazolotriazines |
JP5680639B2 (en) * | 2009-07-02 | 2015-03-04 | サノフイ | Novel 6-morpholin-4-yl-pyrimidin-4- (3H) -one derivatives and their pharmaceutical preparations as inhibitors of AKT (PKB) phosphorylation |
RU2572624C2 (en) * | 2010-03-04 | 2016-01-20 | Мерк Шарп Энд Домэ Корп. | Inhibitors of catechol-o-methyltransferase and thereof application in treatment of psychic disorders |
BR112012030633A2 (en) * | 2010-05-31 | 2016-08-16 | Council Scient Ind Res | antituberculosis agents |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2929394C (en) | 2013-12-19 | 2021-11-16 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
MX2017002610A (en) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE. |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2649141C2 (en) * | 2015-04-20 | 2018-03-30 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 3,4-dimethyl-6-(3-pyridyl)-n-phenyl-2-oxo-1,2,3,6-tetrahydropyrimidine-5-carboxamide with antifungal activity against the candida albicans strain |
JP6980649B2 (en) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | The solid form of the isoquinolinone derivative, the method for producing it, the composition containing it, and the method for using it. |
EA034857B1 (en) | 2015-10-14 | 2020-03-30 | Бристол-Маерс Сквибб Компани | 2,4-dihydroxy-nicotinamides as apj agonists |
CA3008630A1 (en) | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
AR107973A1 (en) | 2016-03-24 | 2018-07-04 | Bristol Myers Squibb Co | 6-HYDROXI-4-OXO-1,4-DIHYDROPIRIMIDIN-5-CARBOXAMIDS AS AN APJ AGONIST |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2020089844A1 (en) * | 2018-11-01 | 2020-05-07 | Ahammune Biosciences Private Limited | Novel imidazole compounds, process for the synthesis and uses thereof |
CN112843058A (en) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | Application of nicotinamide compound in preparation of anti-spinal cord tumor drug |
CN113897631B (en) * | 2021-10-24 | 2023-05-09 | 昆明学院 | Method for electrochemical synthesis of pyridin-2-one derivatives |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249281B (en) | 1963-05-18 | |||
US3320124A (en) | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
BG16042A3 (en) | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
US3962244A (en) | 1971-01-23 | 1976-06-08 | Hoechst Aktiengesellschaft | Benzene sulfonyl ureas |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
US4011324A (en) | 1976-01-20 | 1977-03-08 | Pfizer Inc. | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents |
DE2747357A1 (en) * | 1977-10-21 | 1979-04-26 | Bayer Ag | SUBSTITUTED PYRIMIDINYL (THIONO) (THIOL) PHOSPHOR (PHOSPHON) ACID ESTERS OR. -ESTERAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS INSECTICIDES AND ACARICIDES |
US4281127A (en) | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
DE3177130D1 (en) | 1980-08-30 | 1990-01-11 | Hoechst Ag | AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF. |
JPS5821669A (en) * | 1981-07-30 | 1983-02-08 | Tetsuzo Kato | Preparation of 2-(1-acylaminoalkyl)-6-methyl-4(3h)- pyrimidinone |
JPS6019789A (en) * | 1983-07-12 | 1985-01-31 | Kyorin Pharmaceut Co Ltd | Imidazo(1,5-a)pyrimidine derivative |
JPS6143191A (en) * | 1984-08-07 | 1986-03-01 | Kyorin Pharmaceut Co Ltd | Imidazo(1,5-a)pyrimidine derivative |
GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
GB8530144D0 (en) * | 1985-12-06 | 1986-01-15 | Fujisawa Pharmaceutical Co | Imidazo(1,5-a)heterocyclic compounds |
DE3609598A1 (en) | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-AZOLYLMETHYL-2-ARYL-1,3-DIOXOLANE AND THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING IT AND THEIR USE |
US5187167A (en) | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US4729996A (en) | 1986-05-29 | 1988-03-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor compositions and their methods of use |
GB8707053D0 (en) | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
US4866084A (en) | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
US4808590A (en) | 1987-07-17 | 1989-02-28 | Harbor Branch Oceanographic Institution, Inc. | Antiviral, antitumor and antifungal compositions and their methods of use |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4857530A (en) | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
GB8827820D0 (en) | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
GB8827988D0 (en) | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
GB8829296D0 (en) * | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
US4970226A (en) | 1989-10-03 | 1990-11-13 | Harbor Branch Oceanographic Institution, Inc. | Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents |
US5264439A (en) | 1990-02-13 | 1993-11-23 | Merck & Co., Inc. | Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element |
ZA913730B (en) | 1990-05-30 | 1992-02-26 | Ici Plc | Anti-tumor compounds |
FR2665159B1 (en) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
JPH04147135A (en) * | 1990-10-10 | 1992-05-20 | Konica Corp | New photographic coupler |
JPH04147134A (en) * | 1990-10-09 | 1992-05-20 | Konica Corp | New photographic coupler |
GB9105771D0 (en) | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
JPH0649070A (en) * | 1991-07-23 | 1994-02-22 | Kyorin Pharmaceut Co Ltd | Imidazo(1,5-a)pyrimidine derivative |
US5316906A (en) | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
GB9205907D0 (en) | 1992-03-18 | 1992-04-29 | Cancer Res Inst Royal | Anti-cancer compounds |
US5430148A (en) | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
US5817662A (en) | 1992-11-09 | 1998-10-06 | Cell Therapeutics, Inc. | Substituted amino alkyl compounds |
US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
WO1994015605A1 (en) | 1993-01-14 | 1994-07-21 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
WO1994016704A1 (en) | 1993-01-19 | 1994-08-04 | Cell Therapeutics, Inc. | Oxime-substituted therapeutic compounds |
US5574057A (en) | 1993-02-03 | 1996-11-12 | University Of Utah Research Foundation | Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent |
US5837703A (en) | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
US5342944A (en) | 1993-07-19 | 1994-08-30 | American Cyanamid Company | Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones |
WO1995011235A1 (en) * | 1993-10-20 | 1995-04-27 | The Upjohn Company | Pyrimidinones as antiarthritic and anti-inflammatories |
US20020198326A1 (en) | 1993-11-12 | 2002-12-26 | Taizo Aoyama | Polyolefin resin composition |
CA2113229C (en) | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
AU1831395A (en) | 1994-01-14 | 1995-08-01 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
AU1967495A (en) | 1994-02-18 | 1995-09-04 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
DE4413169C1 (en) * | 1994-04-15 | 1995-05-11 | Daimler Benz Ag | Selector device for a change-speed gearbox |
US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
JPH09165385A (en) | 1994-08-26 | 1997-06-24 | Kyowa Hakko Kogyo Co Ltd | Quinazoline derivative |
US5891879A (en) | 1994-08-31 | 1999-04-06 | Hadasit Medical Research Services & Development Co., Inc. | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |
US5753664A (en) | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
US6245768B1 (en) | 1995-06-05 | 2001-06-12 | Neurogen Corporation | 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO1997008153A1 (en) | 1995-08-30 | 1997-03-06 | Otsuka Pharmaceutical Factory, Inc. | Process for producing quinazolin-4-one derivatives |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
DE19546918A1 (en) | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclic heterocycles |
DE19615262A1 (en) | 1996-04-18 | 1997-10-23 | Bayer Ag | Hetero-linked phenylglycinolamides |
US6008010A (en) | 1996-11-01 | 1999-12-28 | University Of Pittsburgh | Method and apparatus for holding cells |
US5852024A (en) | 1997-02-11 | 1998-12-22 | Hadasit | Treatment and prevention of adhesions |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
AU2107199A (en) | 1998-01-08 | 1999-07-26 | Regents Of The University Of California, The | Kinesin motor modulators derived from the marine sponge (adocia) |
US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
WO2001016114A2 (en) * | 1999-08-27 | 2001-03-08 | Chemocentryx, Inc. | Heterocyclic compounds and methods for modulating cxcr3 function |
US6156758A (en) | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
AU767558B2 (en) * | 1999-09-16 | 2003-11-13 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogenous six-membered ring compounds |
JP4994552B2 (en) * | 1999-09-16 | 2012-08-08 | キュリス,インコーポレイテッド | Hedgehog signaling pathway mediators, compositions and related uses |
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
ES2263501T3 (en) * | 1999-10-27 | 2006-12-16 | Cytokinetics, Inc. | PROCEDURE AND COMPOSITIONS THAT USE QUINAZOLINONES. |
US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
US6380205B1 (en) | 1999-10-29 | 2002-04-30 | Merck & Co., Inc. | 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
JP2003535038A (en) * | 1999-12-30 | 2003-11-25 | スージェン・インコーポレーテッド | 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
DK1939203T3 (en) * | 2000-04-25 | 2015-02-23 | Icos Corp | INHIBITORS OF HUMAN phosphatidyl-inositol 3-kinase DELTA ISOFORM |
EP1307201B1 (en) | 2000-08-01 | 2004-11-24 | Bayer HealthCare AG | Selective pde 2 inhibitors, used as medicaments for improving cognition |
US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1387674B1 (en) * | 2000-10-13 | 2017-01-18 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
KR100883184B1 (en) * | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | CXCR3 antagonists |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
JP4178816B2 (en) * | 2001-03-15 | 2008-11-12 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
DE60208186T2 (en) | 2001-04-09 | 2006-08-24 | Ortho-Mcneil Pharmaceutical Research Inc. | CHINAZOLIN AND CHINAZOLE-RELATED COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISEASES |
US7365199B2 (en) | 2001-04-20 | 2008-04-29 | Fujifilm Corporation | Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
AU2002322585A1 (en) | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
JP2005501887A (en) | 2001-09-05 | 2005-01-20 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | Compositions and uses thereof in the treatment of cancer |
CA2459583A1 (en) | 2001-09-05 | 2003-03-13 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
MXPA04003932A (en) * | 2001-10-26 | 2004-06-18 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase. |
DK1441734T3 (en) * | 2001-10-26 | 2007-06-11 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidine carboxamide inhibitors and HIV integrase |
WO2003043961A2 (en) * | 2001-11-19 | 2003-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
AU2002346471A1 (en) * | 2001-11-20 | 2003-06-10 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
EP1465896A4 (en) | 2001-12-06 | 2006-01-11 | Merck & Co Inc | Mitotic kinesin inhibitors |
EP1551812B1 (en) * | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2002363960B2 (en) | 2001-12-06 | 2008-07-10 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
DE60222302T2 (en) | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | INHIBITORS OF MITOTIC KINESINE |
EP1481077B1 (en) | 2001-12-06 | 2009-11-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
JP2005529076A (en) * | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | Synthesis of quinazolinone |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
DE60336901D1 (en) * | 2002-03-07 | 2011-06-09 | X Ceptor Therapeutics Inc | CHINAZOLINONE MODULATORS OF NUCLEIC RECEPTORS |
JP2006508030A (en) * | 2002-05-09 | 2006-03-09 | サイトキネティクス・インコーポレーテッド | Pyrimidinone compounds, compositions and methods |
EP1553931A4 (en) * | 2002-05-09 | 2006-08-30 | Cytokinetics Inc | Compounds, compositions, and methods |
US20050234080A1 (en) | 2002-05-23 | 2005-10-20 | Coleman Paul J | Mitotic kinesin inhibitors |
US7038048B2 (en) * | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
US20050203110A1 (en) | 2002-05-23 | 2005-09-15 | Coleman Paul J. | Mitotic kinesin inhibitors |
JP2005538062A (en) * | 2002-06-14 | 2005-12-15 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
US20040092561A1 (en) * | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
EP1537089A4 (en) * | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | Compounds compositions and methods |
EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | Compounds, compositions, and methods |
US7557115B2 (en) | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
JP2006515886A (en) * | 2003-01-17 | 2006-06-08 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
EP1601673B1 (en) | 2003-03-07 | 2009-06-10 | AstraZeneca AB | Fused heterocycles and uses thereof |
US7022850B2 (en) * | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
US20050152940A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
-
2003
- 2003-05-02 JP JP2004502928A patent/JP2006508030A/en active Pending
- 2003-05-02 CN CNB03816177XA patent/CN100491358C/en not_active Expired - Fee Related
- 2003-05-02 PL PL03373412A patent/PL373412A1/en unknown
- 2003-05-02 BR BRPI0309892-3A patent/BR0309892A2/en not_active IP Right Cessation
- 2003-05-02 NZ NZ537076A patent/NZ537076A/en unknown
- 2003-05-02 CA CA002485148A patent/CA2485148A1/en not_active Abandoned
- 2003-05-02 KR KR1020047018077A patent/KR20050036911A/en not_active Application Discontinuation
- 2003-05-02 AU AU2003223786A patent/AU2003223786A1/en not_active Abandoned
- 2003-05-02 US US10/429,195 patent/US7166595B2/en not_active Expired - Fee Related
- 2003-05-02 MX MXPA04011074A patent/MXPA04011074A/en active IP Right Grant
- 2003-05-02 WO PCT/US2003/013627 patent/WO2003094839A2/en active Application Filing
- 2003-05-02 EP EP03719989A patent/EP1503993A4/en not_active Withdrawn
- 2003-05-02 RU RU2004135554/04A patent/RU2004135554A/en unknown
- 2003-05-07 MY MYPI20031725A patent/MY140767A/en unknown
- 2003-05-07 TW TW092112382A patent/TW200406387A/en unknown
- 2003-05-08 AR ARP030101617A patent/AR039985A1/en unknown
-
2004
- 2004-11-03 IS IS7520A patent/IS7520A/en unknown
- 2004-11-04 IL IL16504604A patent/IL165046A0/en unknown
- 2004-11-19 NO NO20045043A patent/NO20045043L/en not_active Application Discontinuation
- 2004-12-07 ZA ZA200409881A patent/ZA200409881B/en unknown
-
2006
- 2006-11-15 US US11/600,683 patent/US7482343B2/en not_active Expired - Fee Related
-
2007
- 2007-11-20 IL IL187528A patent/IL187528A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20045043L (en) | 2005-02-08 |
CA2485148A1 (en) | 2003-11-20 |
KR20050036911A (en) | 2005-04-20 |
MY140767A (en) | 2010-01-15 |
IS7520A (en) | 2004-11-03 |
IL187528A0 (en) | 2008-03-20 |
NZ537076A (en) | 2007-06-29 |
US7482343B2 (en) | 2009-01-27 |
WO2003094839A3 (en) | 2004-09-16 |
RU2004135554A (en) | 2006-01-20 |
PL373412A1 (en) | 2005-08-22 |
US7166595B2 (en) | 2007-01-23 |
BR0309892A2 (en) | 2011-04-05 |
IL165046A0 (en) | 2005-12-18 |
EP1503993A2 (en) | 2005-02-09 |
MXPA04011074A (en) | 2005-06-08 |
EP1503993A4 (en) | 2006-05-03 |
CN1665788A (en) | 2005-09-07 |
CN100491358C (en) | 2009-05-27 |
JP2006508030A (en) | 2006-03-09 |
WO2003094839A2 (en) | 2003-11-20 |
TW200406387A (en) | 2004-05-01 |
AR039985A1 (en) | 2005-03-09 |
US20070135432A1 (en) | 2007-06-14 |
AU2003223786A1 (en) | 2003-11-11 |
ZA200409881B (en) | 2006-04-26 |
US20040077662A1 (en) | 2004-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003094839A3 (en) | Pyrimidinone compounds, compositions and methods | |
WO2004018058A3 (en) | Compounds, compositions, and methods | |
WO2003088903A3 (en) | Compounds, compositions, and methods | |
WO2003103575A3 (en) | Compounds, compositions, and methods | |
WO2004009036A3 (en) | Compounds compositions and methods | |
WO2006113432A3 (en) | Compounds, compositions and methods | |
WO2005107762A3 (en) | Certain chemical entities, compositions, and methods | |
WO2007056469A3 (en) | Certain chemical entities, compositions, and methods | |
WO2007056143A3 (en) | Certain chemical entities, compositions, and methods | |
WO2003082208A8 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
NO20052267L (en) | Compounds, Preparations and Methods | |
WO2007056078A3 (en) | Certain chemical entities, compositions, and methods | |
PL358412A1 (en) | Methods and compositions utilizing quinazolinones | |
WO2004005460A3 (en) | Antisense modulation of hmg-coa reductase expression | |
WO2006004703A3 (en) | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | |
WO2004006865A3 (en) | Compounds, compositions, and methods | |
WO2005030144A3 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
WO2004034972A3 (en) | Compounds, compositions, and methods | |
WO2004064741A3 (en) | Compounds, compositions, and methods | |
WO2005046588A3 (en) | Compounds, compositions, and methods | |
WO2004026226A3 (en) | Compounds, compositions and methods | |
WO2004022005A3 (en) | Regulation of the growth hormone/igf-1 axis | |
WO2004100873A3 (en) | Compounds, compositions, and methods | |
WO2005042697A3 (en) | Compounds, compositions and methods | |
WO2004024086A3 (en) | Compounds, compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-501796 Country of ref document: PH |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 47/2003 REPLACE "(71) APPLICANTS AND (72) INVENTORS" BY "(72) INVENTORS; AND (75) INVENTORS/APPLICANTS (FOR US ONLY)" |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 373412 Country of ref document: PL Ref document number: 165046 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2485148 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/011074 Country of ref document: MX Ref document number: 2004502928 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047018077 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003719989 Country of ref document: EP Ref document number: 3751/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003223786 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/09881 Country of ref document: ZA Ref document number: 200409881 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537076 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004135554 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003816177X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003719989 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047018077 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 187528 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502896 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: PI0309892 Country of ref document: BR Kind code of ref document: A2 Effective date: 20041109 |